Francesca Moro Maria, Efisia Lecca Maria, Alessandra Ghillani M, Marianna Alacqua, Giovanni Carta Mauro
Division of Psychiatry, Department of Public Health, University of Cagliari, Italy;
Medical Department, AstraZeneca Italy SpA.
Clin Pract Epidemiol Ment Health. 2014 Mar 7;10:42-7. doi: 10.2174/1745017901410010042. eCollection 2014.
Undiagnosed and therefore inadequately treated hypomanic symptoms may be a leading cause of drug resistance in depression diagnosed as unipolar (major depressive disorder, MDD). The purpose of the IMPROVE study was to identify the rate of misdiagnoses in patients with treatment-resistant MDD by screening for the presence of previous hypomanic episodes, and to study the characteristics of those patients with a positive history of hypomania.
Patients attending 29 psychiatric units throughout Italy with a diagnosis of MDD who were resistant to anti-depressant treatment were included in this multicentre, observational single visit study. The Hypomania Checklist 32 (HCL-32) was administered to detect underlying bipolarity.
Among the 466 enrolled patients, 256 (57.40%) were positive at screening for a previous hypomanic episode (HCL-32 ≥12), therefore suggesting a misdiagnosis. These patients scored higher than those with a negative history in both the "active/elated hypomania" (11.27±3.11 vs 3.57±3.05; P<0.0001) and "irritable/risk-taking hypomania" (2.87±2.03 vs 2.06±1.73; P<0.001) HCL-32 sub-scales. Patients with a positive history of hypomania were younger, had a higher number of previous depressive episodes and a higher frequency of comorbid conditions compared to those with a negative history.
This study suggests that screening for hypomania in MDD-resistant patients facilitates identification of a notable proportion of undiagnosed cases of bipolar spectrum disorder. Patients with a positive history of hypomania at screening had a demographic/clinical bipolar-like profile that included young age, higher number of previous depressive episodes and higher frequency of comorbid conditions. They also had both higher active and irritable hypomania symptom scores.
未被诊断因而未得到充分治疗的轻躁狂症状可能是被诊断为单相抑郁(重度抑郁症,MDD)的患者产生耐药性的主要原因。IMPROVE研究的目的是通过筛查既往轻躁狂发作的情况来确定难治性MDD患者的误诊率,并研究有轻躁狂病史患者的特征。
本多中心、观察性单次就诊研究纳入了意大利29个精神科单位中被诊断为MDD且对抗抑郁治疗耐药的患者。使用轻躁狂症状清单32(HCL-32)来检测潜在的双相情感障碍。
在466名入组患者中,256名(57.40%)在筛查时既往有轻躁狂发作呈阳性(HCL-32≥12),因此提示存在误诊。这些患者在“活跃/欣快轻躁狂”(11.27±3.11对3.57±3.05;P<0.0001)和“易激惹/冒险轻躁狂”(2.87±2.03对2.06±1.73;P<0.001)HCL-32子量表上的得分均高于无该病史的患者。与无轻躁狂病史的患者相比,有轻躁狂病史的患者更年轻,既往抑郁发作次数更多,合并症发生率更高。
本研究表明,对难治性MDD患者进行轻躁狂筛查有助于识别相当比例未被诊断的双相谱系障碍病例。筛查时有轻躁狂病史的患者具有人口统计学/临床双相情感障碍样特征,包括年龄较小、既往抑郁发作次数较多以及合并症发生率较高。他们的活跃和易激惹轻躁狂症状评分也更高。